The Price for Remdesivir
Gilead set the cost at $520 per dose in the United States
Gilead sets the pricing for remdesivir. The pharmaceutical company announced on Monday that it set pricing for its remdesivir treatment at $520 per dose in the United States. The company has been donating doses to the U.S. government since it received emergency use authorization in May.
Specifically, the company will sell remdesivir for $390 per vial to governments “of developed countries” around the world and the price for U.S. private insurance companies will stand at $520 per vial.
The majority of patients treated with remdesivir will receive a five-day treatment course using six vials of remdesivir, the company said. That would bring the government cost to $2,340 for patients on the five-day treatment and $3,120 for commercially insured patients.
The longer, 10-day treatment course will cost governments $4,290 per patient and $5,720 for a U.S. patient with private insurance.
Here’s two stories we recommend to understanding the pricing and the debate around it:
Gilead's coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance
Gilead Sciences announced Monday the pricing for its coronavirus treatment remdesivir, saying it will cost $3,120 for a…